跳至主要内容
临床试验/NCT03787069
NCT03787069已完成3 期

Effect of Intravenous Lignocaine vs Placebo on Hemodynamic Response During Intubation

Indus Hospital and Health Network1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2017年12月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
MAP

研究概览

简要总结

To assess the mean hemodynamic responses post-intubation in patients given intravenous lignocaine pre-intubation as compared to a placebo pre-intubation in patients undergoing laryngoscopy surgery

详细描述

After identifying the candidate, details will be carefully discussed with the subject. The subject (or, when necessary, the parent or legal guardian if the subject is younger than 18 years of age or under guardianship) will be read the approved protocol consent form. Patients who have given informed consent to participate in the study will be randomized into one of the two study arms one day before the procedure. The study team present will open the sealed envelopes provided by the Indus Hospital Research Center's Clinical Research Unit (CRU) that provides the study arm allocation. The envelopes will follow the SNOSE protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
20 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •ASA I and II
  • •Age 20-60 years
  • •Mallampatti , II
  • •All surgeries are done under GA
  • •Both genders
  • •Those patients giving informed consent

排除标准

  • •Difficult airway assessed during pre-op anaesthesia assessment
  • •Unanticipated difficult airway based on the previous history of difficult intubation
  • •BMI >30,
  • •Micrognathia and microglossia based on pre-op anaesthesia assessment,
  • •Diabetic patient with autonomic dysfunction liver disease, cardiovascular disease, pheochromocytoma, Cushing syndrome
  • •Patients who do not give informed consent

研究组 & 干预措施

Lignocaine group

Experimental

This group will be given 1.5 mg/kg I/V lignocaine before intubation

干预措施: iv Lignocaine vs placebo (Drug)

Placebo

Placebo Comparator

This group will be given 6 ml normal saline before intubation

干预措施: iv Lignocaine vs placebo (Drug)

结局指标

主要结局

MAP

时间窗: post-intubation 3 minutes to 10 minutes

mean arterial pressure

Pulse

时间窗: post-intubation 3 minutes to 10 minutes

Heart rate

次要结局

未报告次要终点

研究者

发起方
Indus Hospital and Health Network
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Intravenous Lignocaine vs Placebo | 临床试验